GATC Health Advances Research Capabilities by Commencing Drug Discovery in Their West Virginia Lab

IRVINE, CA, USA – November 17, 2024 – Informing North-Central West Virginia residents since 1864, The Dominion Post recently featured GATC Health’s progress at its WVU Innovation Center headquarters. The company’s disruptive AI technology is enabling significant advances, not only in science, but in the way clinical development of drugs is insured and financed through a partnership with Lloyd’s of London, Acrisure, and MCI. The team in West Virginia is on the front lines of these advancements.

Excerpted from the story:
“An early stage biotech company might spend tens of millions on pre-clinical trials, then need hundreds of millions more for clinical trials. Only 40-50 new drugs survive the process each year.

“GATC’s MAT platform takes that initial four- to six-year process and reduces it to 18 months, and they’re looking to reduce it to 12 months. And these AI-crafted compounds will have a greater likelihood of surviving the pre-clinical (generally animal) and clinical (human) trials for FDA approval. They want to improve the 5-10% success rate to 90%.”

Read the full story

About GATC Health

GATC Health Corp is a technology company revolutionizing drug discovery and development through its transformative AI platform and approach. The company’s validated and proprietary Multiomics Advanced Technology™ (MAT) simulates human biochemistry’s billions of interactions to rapidly create novel therapeutics, identify and confirm targets, accelerate development, and de-risk drug pipelines by predicting efficacy, safety, and off-target effects.